CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
1 Online-Ressource.
Sprache
Englisch

Erschienen in
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing ; volume:7 ; number:1 ; day:13 ; month:8 ; year:2024 ; pages:1-15 ; date:12.2024
Communications biology ; 7, Heft 1 (13.8.2024), 1-15, 12.2024

Urheber
Liao, Chen-Yi
Engelberts, Patrick
Ioan-Facsinay, Andreea
Klip, Janna Eleonora
Schmidt, Thomas
Ruijtenbeek, Rob
Danen, Erik H. J.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1038/s42003-024-06682-9
URN
urn:nbn:de:101:1-2411010804242.545900828521
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:27 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Liao, Chen-Yi
  • Engelberts, Patrick
  • Ioan-Facsinay, Andreea
  • Klip, Janna Eleonora
  • Schmidt, Thomas
  • Ruijtenbeek, Rob
  • Danen, Erik H. J.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3

Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors

Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases

Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

Anti-tumor activity, pharmacology and toxicology of EpCAM-, CD3-bispecific single-chain antibodies

Hochschulschrift

Anti-tumor activity, pharmacology and toxicology of EpCAM-, CD3-bispecific single-chain antibodies

Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies

Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

Verbundene Objekte